QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NYSE:HAE

Haemonetics - HAE Stock Forecast, Price & News

$78.18
+1.57 (+2.05%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$76.73
$78.62
50-Day Range
$74.48
$90.60
52-Week Range
$48.67
$91.39
Volume
328,250 shs
Average Volume
433,824 shs
Market Capitalization
$3.94 billion
P/E Ratio
42.26
Dividend Yield
N/A
Price Target
$101.00

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
29.2% Upside
$101.00 Price Target
Short Interest
Healthy
2.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.53mentions of Haemonetics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$215,190 Sold Last Quarter
Proj. Earnings Growth
11.90%
From $2.94 to $3.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

93rd out of 988 stocks

Surgical & Medical Instruments Industry

8th out of 101 stocks


HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Medtronic's (MDT) Affera Ablation System Gets CE Mark
Illumina (ILMN) Unveils Complete Long Reads Technology
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Bull of the Day: Haemonetics (HAE)
Molina (MOH) to Post Q4 Earnings: What You Should Expect
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Company Calendar

Last Earnings
2/07/2023
Today
3/20/2023
Fiscal Year End
3/31/2023
Next Earnings (Estimated)
5/09/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
2,821
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$101.00
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+29.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$43.38 million
Pretax Margin
10.99%

Debt

Sales & Book Value

Annual Sales
$993.20 million
Cash Flow
$4.66 per share
Book Value
$14.66 per share

Miscellaneous

Free Float
49,616,000
Market Cap
$3.94 billion
Optionable
Optionable
Beta
0.43

Social Links


Key Executives

  • Christopher A. SimonChristopher A. Simon
    President, Chief Executive Officer & Director
  • James C. Darecca
    Executive VP, Chief Financial & Accounting Officer
  • Anila LingamneniAnila Lingamneni
    Chief Technology Officer & Executive VP
  • Laurie A. MillerLaurie A. Miller
    Chief Human Resources Officer & Senior VP
  • David James Wilson
    President-Plasma Business Unit













HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2023?

6 brokers have issued 1-year price objectives for Haemonetics' stock. Their HAE share price forecasts range from $88.00 to $115.00. On average, they predict the company's stock price to reach $101.00 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2023?

Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have decreased by 0.6% and is now trading at $78.18.
View the best growth stocks for 2023 here
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier earned $305.30 million during the quarter, compared to the consensus estimate of $300.47 million. Haemonetics had a net margin of 8.48% and a trailing twelve-month return on equity of 19.84%. The firm's quarterly revenue was up 17.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.84 EPS.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided earnings per share guidance of $2.90-$3.00 for the period, compared to the consensus EPS estimate of $2.92. The company issued revenue guidance of $1.14 billion-$1.16 billion, compared to the consensus revenue estimate of $1.14 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Steelhead Partners LLC (9.91%), Neuberger Berman Group LLC (7.68%), Fisher Asset Management LLC (2.19%), Schroder Investment Management Group (1.89%), Geode Capital Management LLC (1.80%) and Dimensional Fund Advisors LP (1.45%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $78.18.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $3.94 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $1.85 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 2,821 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 3/20/2023 by MarketBeat.com Staff